Graduation in Medicine and Surgery, Oviedo University Medical School, Oviedo, Spain (1980)

RAMON CACABELOS, M.D., Ph.D., D.M.Sc.

CURRICULUM VITAE Summary

Date of Birth: May 18, 1955 (Cambados, Pontevedra, Spain)

Home Address: Ave Arteixo, 69-2C, 15007-Coruña, Spain

Affiliation

Professor & Chairman of Genomic Medicine, Camilo José Cela University, Madrid, Spain

Director General, EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, Coruña, Spain.

Education

Graduate in Medicine and Surgery, Oviedo University Medical School, Oviedo, Spain (1980)

International Fellowship, Ministry of Education, Science and Culture of Japan, Department of Psychiatry, Osaka University Medical School, Osaka, Japan (1981-1983)

International Fellowship, Ministry of Education, Science and Culture of Japan, Postgraduate I-IV, Department of Psychiatry, Osaka University Medical School, Osaka, Japan (1983-1987)

Ph.D. (Medicine & Surgery), SantiagoUniversityMedicalSchool, Santiago de Compostela, Spain (1985)

Ph.D., D.M. Sci. (Doctor in Medical Science/Internal Medicine/Psychiatry), OsakaUniversityMedicalSchool, Osaka, Japan (1987)

Specialist in Psychiatry (Osaka University Medical School)(1987)

Positions

Associate Professor of Psychiatry, Department of Psychiatry, Santiago University Medical School, Santiago de Compostela, Spain (1987-1989)

Tenure Professor, Department of Human Physiology, Complutense University Medical School, Madrid, Spain (1989-1995)

President of EuroEspes Corp. (1991-2013)

Director, Institute for Central Nervous System Disorders and Genomic Medicine, La Coruña, Spain (1991-)

President, EuroEspes Foundation (1992-2013)

President, Spanish Association of Neurogerontology and Neurogeriatrics (1994-2005)

Director General, EuroEspes Biomedical Research Center, La Coruña, Spain (1995-2013)

Director, Department of Clinical Neurosciences, CIBE, La Coruña, Spain (1995-)

President, EuroEspes Biotechnology (EBIOTEC), La Coruña, Spain, (2001-2013)

President, Ebiotec Foundation, La Coruña, Spain (2003-2008)

President, Spanish Society of Genomic Medicine (2005-)

President, World Association of Genomic Medicine (2008-)

Professor & Chairman, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain (2003-2013)

Professor & Chairman, Chair of Genomic Medicine, Camilo José Cela University, Madrid, Spain (2013-)

Vice-Rector of Science & Research, Camilo José Cela University, Madrid, Spain

Publications

Publications: Original papers (>400), chapters and reviews (>500), Abstracts and Congress Communications (645), Books (17), Other publications (155)

Editor-in-Chief: ANNALS OF PSYCHIATRY/BASIC AND CLINICAL NEUROSCIENCES (1990-2004)

Editor-in-Chief: Research Reports

Editor-in-Chief: NEUROGERONTOLOGY & NEUROGERIATRICS (1993-2004)

Editor-in-Chief, The EuroEspes Journal, Gen-T (2007-)

Editor-in-Chief: World Guide for Drug Use and Pharmacogenomics (2012-)

Selected Papers (2000-2015)

Cacabelos, R., Álvarez, X.A., Fernández-Novoa, L., Lombardi, V.R.M. A pharmacogenomic approach to Alzheimer’s disease. Acta Neurol. Scand., 102 (Suppl. 176):12-19 (2000).

Cacabelos, R. Psychogeriatric research: A conceptual introduction to aging and geriatric neuroscience. Psychogeriatrics, 1:158-188 (2001).

Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. Min. Rev. Medic. Chem., 2:59-84 (2002).

Cacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med., 34:357-379 (2002).

Cacabelos, R. The application of functional genomics to Alzheimer’s disease. Pharmacogenomics, 4:597-621 (2003).

Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Corzo, L., Pichel, V., Kubota, Y. Cerebrovascular risk factors in Alzheimer’s disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res., 25:567-580 (2003).

Cacabelos, R., Corzo, L., Fernández-Novoa, L., Lombardi, V. Histamine in Alzheimer’s disease pathogenesis: Biochemistry and functional genomics. Meth. Find. Exp. Clin. Pharmacol., 26(Suppl. 2):9-16 (2004).

Cacabelos, R., Fernández-Novoa, L., Corzo, L., Pichel, V., Lombardi, V., Kubota, Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth. Find. Exp. Clin. Pharmacol., 26:421-444 (2004).

Cacabelos, R., Fernández-Novoa, L., Corzo, L., Amado, L., Pichel, V., Lombardi, V., Kubota, Y. Phenotypic profiles and functional genomics in Alzheimer’s disease and in dementia with a vascular component. Neurol. Res., 26:459-480 (2004).

Cacabelos, R. Genomic characterization of Alzheimer’s disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 5:1049-1105 (2004).

Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Kubota, Y., Takeda, M. Molecular genetics of Alzheimer’s disease and aging. Meth. Find. Exp. Clin. Pharmacol., 27(Suppl. A):1-573 (2005).

Cacabelos, R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease. Aging Health, 1:303-348 (2005).

Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease. Expert Opin. Pharmacother., 6:1967-1987 (2005).

Cacabelos, R., Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer’s disease. Drugs Future, 31(Suppl. B):5-146 (2006).

Cacabelos, R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol., 29(Supp. A):1-91 (2007).

Takeda, M., Cacabelos, R. (Eds.). Alzheimer’s disease genomics. Cognition and Dementia, 6 (Suppl.):7-113 (2007).

Cacabelos, R. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat., 3:303-333 (2007).

Cacabelos, R., Llovo, R., Fraile, C., Fernández-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Cur. Alzheimer Res., 4:479-500 (2007).

Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer’s disease. Mol. Diag. Ther., 11:385-405 (2007).

Cacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 258(Suppl. 1):28-47 (2008).

Cacabelos, R. Influence of pharmacogenetic factors on Alzheimer’s disease therapeutics. Neurodegenerative Dis., 5:176-178 (2008).

Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. Meth Mol. Biol., 448:213-357 (2008).

Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. In: Pharmacogenomics and Personalized Medicine. Cohen, N. (Ed.). pp. 317-368 (2008).

Cacabelos, R. Pleiotropic effects of Apolipoprotein E in dementia: Influence on functional genomics and pharmacogenetics. Adv. Behav. Biol., 57:355-367 (2008).

Cacabelos, R. Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders. In: The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Vol. IV: Molecular Genetic and Genomic Markers. Ritsner, M.S. (Ed.). Springer, pp. 3-63 (2009).

Cacabelos, R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev. Mol. Diag., 9:567-611 (2009).

Cacabelos, R., Martínez-Bouza, R. Genomics and pharmacogenomics of schizophrenia. CNS Neuroscience & Therapeutics. DOI: 10.111_j.1755-5949.2010.00187.

Cacabelos, R., Martínez-Bouza, R. Genomics and pharmacogenomics of dementia. CNS Neurosciences & Therapeutics. DOI: 10.111_j.1755-5949.2010.00189.

Cacabelos, R., Fernández-Novoa, L., Martínez-Bouza, R., McKay, A., Carril, J.C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., Nebril, L., Alcaraz, M., Rodríguez, S., Casas, A., Couceiro, V., Alvarez, A. Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants. Pharmaceuticals 3:3040-3100 (2010); doi: 10.3390/ph3103040.

Takeda, M., Martínez, R., Kudo, T., Tanaka, T., Okochi, M., Tagami, S., Morihara, T., Hashimoto, R., Cacabelos, R. Apolipoprotein E and central nervous system disorders: Reviews of clinical findings. Psychiat Clin Neurosci 64:592-607 (2010).

Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Carril, J.C., Corzo, L., Carrera, I., Tellado, I., Martínez, R., McKay, A., Takeda, M. Genomics of schizophrenia and psychotic disorders. Gen-T 3:6-86 (2011).

Cacabelos, R., Hashimoto, R., Takeda, M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiat Clin Neurosci 65:3-19 (2011).

Cacabelos, R., Martínez-Bouza, R., Carril, J.C., Fernández-Novoa, L., Lombardi, V., Carrera, I., Corzo, L., McKay, A. Genomics and Pharmacogenomics of brain disorders. Curr. Pharmaceut. Biotech., 13:674-725 (2012).

Cacabelos, R., Martínez, R., Fernández-Novoa, L., Carril, J.C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., Takeda, M. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int J Alzheimer Dis., doi:10.1155/2012/518901.

Carrera, I., Etcheverría, I., Li, Y., Fernández-Novoa, L., Lombardi, V., Vigo, C., Palacios, H.H., Benberin, V., Cacabelos, R., Aliev, G. Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine. BioMed Research International (2013).

Cacabelos R, López-Muñoz F. The ABCB1 transporter in Alzheimer’s disease. Clin Exp Pharmacol 2014; 4: e128. Doi:10.4172/2161-1459.1000e128.

Cacabelos R. The pathogenic component of the APOE-TOMM40 region in Alzheimer’s disease: Its implications in Metabolomics and Pharmacogenomics. Metabolomics 2014; 4: 1000e129. Doi:10.4172/2153-0769.1000e129.

Cacabelos R. Metabolomics of epigenetic drugs: precautionary measures. Metabolomics 2014; 4: e126. Doi:10.4172/2153-0769.1000e126.

Cacabelos R, Torrellas C, López-Muñoz F. Epigenomics of Alzheimer’s disease. J Exp Med 2014; 6(3):75-82.

Cacabelos R1, Torrellas C.Epigenetic drug discovery for Alzheimer's disease.Expert Opin Drug Discov.2014 Sep;9(9):1059-86. doi: 10.1517/17460441.2014.930124. Epub 2014 Jul 3.See comment in PubMed Commons below

Cacabelos R1, Cacabelos P, Torrellas C, Tellado I, Carril JC.Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.Methods Mol Biol. 2014;1175:323-556. doi: 10.1007/978-1-4939-0956-8_13.

Cacabelos R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.Drug Dev Res. 2014 Sep;75(6):348-65. doi: 10.1002/ddr.21219.

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, Corzo D, Carril JC, Roses AD. APOE-TOMM40 in the Pharmacogenomics of demetia. J Pharmacogenomics Pharmacoproteomics 2014; 5: 135. Doi:10.4172/2153-0645.1000135.

Research Interest

-Pharmacogenomics of CNS disorders

-Pharmacoepigenomics of CNS disorders

-Biomarkers for CNS disorders

-Drug development

-Biopharmaceuticals

-Nutraceuticals